AB0465 EFFICACY AND SAFETY OF IGURATIMOD IN PATIENTS WITH PRIMARY SJOGREN SYNDROME: A FOLLOW-UP STUDY

Abstract

Background: Primary Sjogren syndrome (pSS) is a chronic autoimmune disorder affecting 0.2–3% of the population. However, there are currently no effective systemic therapies. Anti-Ro, anti-La and rheumatoid factor(RF) as well as hyper γ-globulinaemia indicate a degree of B cell hyperactivity. In the recent ten years, iguratimod (T-614) has been used to treat RA as a novel immunomodulatory, which functions by suppressing the production of some inflammatory cytokines, as well as reducing immunoglobulin production by acting directly on human B lymphocytes without affecting B lymphocyte proliferation. Objectives: We evaluated the effectiveness and safety of iguratimod on pSS patients in this follow up study. Methods: A total of 21 pSS patients without severe systemic damage needing corticosteroid were recruited to receive iguratimod 25mg Bid for 12 weeks. Results: Among them, 1 patient and 2 patients withdrew because of kidney dysfunction and ineffectiveness. For those 18 patients who finished the follow up, 94.4% were females and average age were 46.5±13.8 year-old with median disease duration of 22.0 (9.8, 58.5) months. Compared with baseline, ESSDAI score, hyperglobulinaemia and ESR was significant decreased after iguratimod treatment (Table). Two of the 18 patients presented with decreased white blood cell count. This side effect ameliorated in one patient after tapering the dose to 25mg Qd and in another patient after 2 weeks without any intervention. Conclusion: This is the first follow study of iguratimod in pSS to show benefit with good tolerance.